MacroGenics (MGNX) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12 month target prices for MacroGenics' stock. Their MGNX share price forecasts range from $5.00 to $17.00. On average, they predict the company's share price to reach $11.40 in the next year. This suggests a possible upside of 123.5% from the stock's current price.
View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts.

MacroGenics' stock was trading at $6.71 on January 1st, 2023. Since then, MGNX stock has decreased by 24.0% and is now trading at $5.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our MGNX earnings forecast.

MacroGenics, Inc. (NASDAQ:MGNX) issued its quarterly earnings results on Wednesday, March, 15th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.51. The biopharmaceutical company earned $73.10 million during the quarter, compared to analysts' expectations of $75.40 million. MacroGenics had a negative trailing twelve-month return on equity of 70.69% and a negative net margin of 55.24%.

ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.70%), Armistice Capital LLC (9.64%), Wasatch Advisors LP (2.14%), State Street Corp (2.11%), Acadian Asset Management LLC (1.99%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGNX stock can currently be purchased for approximately $5.10.

MacroGenics (NASDAQ:MGNX) has a market capitalization of $315.38 million and generates $151.94 million in revenue each year. The biopharmaceutical company earns $-119,760,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

The company employs 427 workers across the globe.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.